The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives
Publication in refereed journal

替代計量分析
.

其它資訊
摘要Aberrant epigenetic reprogramming occurs frequently in the development of tumors. Histone H3 lysine 27 trimethylation (H3K27me3) exerts a repressive epigenetic mark on a large number of genes. UTX and JMJD3 are the only two histone demethylases which activate gene expression via demethylating H3K27me3 to H3K27me2 or H3K27me1. Current studies show that dysregulation of these two proteins are heavily linked to oncogenesis in various tissue types. Accumulating evidence suggested that there is remarkable therapeutic potential of targeting JMJD3 or UTX in different types of cancer. Herein, we shall give a brief review on the functional roles of JMJD3 and UTX in cancers and evaluate the available compounds and agents targeting UTX and JMJD3. Finally, we also discuss the several modalities that target UTX and JMJD3 for cancer therapy. This review will help to develop novel strategies to abolish or restore effects of UTX and JMJD3 in the pathogenesis of cancer.
著者Zhangang XIAO, Jing SHEN, Lin ZHANG, Longfei LI, Mingxing LI, Wei HU, Zhijie LI, Chi Hin CHO
期刊名稱Current Medicinal Chemistry
出版年份2016
月份7
卷號23
期次32
出版社BENTHAM SCIENCE PUBL LTD
頁次3687 - 3696
國際標準期刊號0929-8673
電子國際標準期刊號1875-533X
語言英式英語
關鍵詞UTX, JMJD3, H3K27, cancer, therapeutic target
Web of Science 學科類別Biochemistry & Molecular Biology;Chemistry, Medicinal;Pharmacology & Pharmacy;Biochemistry & Molecular Biology;Pharmacology & Pharmacy

上次更新時間 2021-25-01 於 02:30